Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study

Blaszak,Michael; El‑Masri,Maher; Hirmiz,Khalid; Mathews,John; Omar,Abeer; Elfiki,Tarek; Gupta,Rasna; Hamm,Caroline; Kanjeekal,Sindu; Kay,Amin; Kulkarni,Swati; Ghafoor,Akmal

doi:10.3892/mco.2017.1179

Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study

Authors:
- Michael Blaszak
- Maher El‑Masri
- Khalid Hirmiz
- John Mathews
- Abeer Omar
- Tarek Elfiki
- Rasna Gupta
- Caroline Hamm
- Sindu Kanjeekal
- Amin Kay
- Swati Kulkarni
- Akmal Ghafoor
View Affiliations

Affiliations: Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada, Faculty of Nursing, University of Windsor, Windsor, Ontario, ON N9B 3P4, Canada
Published online on: March 1, 2017 https://doi.org/10.3892/mco.2017.1179
Pages: 583-588

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present retrospective chart review examined the overall survival (OS) of patients with pancreatic ductal adenocarcinoma based on the disease stage in a sample of 296 patients with pancreatic cancer. Secondary outcome measurements included OS in chemotherapy vs. supportive treatment groups among metastatic patients, OS based on response to chemotherapy among metastatic patients, and OS and disease free survival (DFS) in surgically resected disease with vs. without adjuvant therapy. Data were analyzed using Kaplan‑Meier and multivariate cox‑regression analyses based on a 95% confidence interval (CI) or an α‑value of 0.05. OS was significantly different based on the disease stage, with 3.63 (95% CI, 2.84‑4.43), 6.57 (95% CI, 4.06‑9.08) and 15.57 (95% CI, 11.79‑19.35) months in the advanced, locally advanced, and localized disease groups, respectively. OS was higher in metastatic‑stage patients who received chemotherapy [6.07 months (95% CI, 4.75‑7.39)] compared with those who received supportive therapy alone [2.50 months (95% CI, 2.16‑2.84; P<.001)]. Metastatic‑stage patients with partial or stable response to chemotherapy had higher OS [10.53 months (95% CI, 6.35‑14.72)] in comparison with those with progression [6.33 months (95% CI, 5.79‑6.88)] or an undocumented response [3.30 months (95% CI, 1.76‑4.84; P<0.001)]. In patients who underwent surgical resection of localized disease, adjuvant therapy increased the adjusted OS and DFS as compared with surgical excision alone (P=0.013; 95% CI, 0.278‑0.862). Positive margins reduced OS [hazard ratio (HR) 2.670; 95% CI, 1.467‑4.860]. The present single‑site study has demonstrated that OS may markedly differ on the basis of the disease status at the time of diagnosis. Metastatic‑stage patients with stable or partial response to chemotherapy had an increased OS, as did surgical patients with localized disease who received adjuvant treatment, after adjusting for margin status.

View Figures

View References

1	Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G and Biasco G: Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). Oncol Rep. 23:1183–1192. 2010. View Article : Google Scholar : PubMed/NCBI
2	Sen N, Falk S and Abrams R: Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer. Clin Oncol (R Coll Radiol). 26:551–559. 2014. View Article : Google Scholar : PubMed/NCBI
3	Seufferlein T, Bachet JB, Van Cutsem E and P; ESMO Guidelines Working Group Rougier: Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23 Suppl 7:vii33–vii40. 2012. View Article : Google Scholar : PubMed/NCBI
4	Preis M and Korc M: Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther. 9:754–763. 2010. View Article : Google Scholar : PubMed/NCBI
5	Kleger A, Perhofer L and Seufferlein T: Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol. 25:1260–1270. 2014. View Article : Google Scholar : PubMed/NCBI
6	Vaccaro V, Sperduti I and Milella M: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 365:768–769. 2011. View Article : Google Scholar : PubMed/NCBI
7	Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, et al: Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 31:23–29. 2013. View Article : Google Scholar : PubMed/NCBI
8	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
9	Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, et al: Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 20:143–150. 2015. View Article : Google Scholar : PubMed/NCBI
10	Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
11	Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 304:1073–1081. 2010. View Article : Google Scholar : PubMed/NCBI
12	Miller RC, Iott MJ and Corsini MM: Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium. Int J Radiat Oncol Biol Phys. 75:364–368. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chuong MD, Boggs DH, Patel KN and Regine WF: Adjuvant chemoradiation for pancreatic cancer: What does the evidence tell us? J Gastrointest Oncol. 5:166–177. 2014.PubMed/NCBI
14	Ouettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, et al: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013. View Article : Google Scholar : PubMed/NCBI
15	Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA and Willett CG: Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 18:1319–1326. 2011. View Article : Google Scholar : PubMed/NCBI
16	Moghanaki D, Mick R, Furth EE, Sohal D, Salmon PM, Behbahani A, Morgans AK, Miller SM, Giantonio BJ, Whittington RW, et al: Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma. JOP. 12:438–444. 2011.PubMed/NCBI
17	Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, et al: Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 26:3503–3510. 2008. View Article : Google Scholar : PubMed/NCBI
18	Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI